PCF-39 is a new hypoxantine derivative capable of activating mature phagocytes. Effects of this drug on differentiation of a human histiocytic lymphoma-derived cell line (U-937) and promyelocytic leukemia-derived cell line (HL-60) were studied in comparison with other differentiation inducers as immune (gamma) interferon (γ-IFN) and 12-0-tetradecanoyl-13-phorbol acetate (TPA). When cultured with γ-IFN (50-1000 U/ml) or TPA (10-100 nM), U-937 cells showed gross morphologic and microscopic changes consisting of clumping, increased prominence of cytoplasmic granules and membrane ruffling. In contrast, U-937 cells treated with different doses of PCF-39 grew as a single cell suspension cultures without morphological changes, as untreated cells. After culture with γ-IFN and TPA the number of Fc receptor sites on U-937 cells increased dramatically, while no significant differences were seen in PCF-39-treated cells compared to control. Gamma-IFN and TPA treatment also enhanced TPA-induced superoxide production and alfa naftyl acetate estarase (alfa-NAE) staining by U-937 cells, while PCF-39 did not. In contrast, HL-60, which differentiates towards cells of the monocyte lineage in response to TPA (based on the above criteria) slightly differentiated when cultured with γ-IFN (10-20%) and did not differentiate under PCF-39 treatment.
|Number of pages||6|
|Journal||EOS Rivista di Immunologia ed Immunofarmacologia|
|Publication status||Published - 1987|
ASJC Scopus subject areas